Product InformationRegistration Status: Active
SOLIAN TABLET 400mg is approved to be sold in Singapore with effective from 2001-01-03. It is marketed by SANOFI-AVENTIS SINGAPORE PTE LTD, with the registration number of SIN11463P.
This product contains Amisulpride 400mg in the form of TABLET, FILM-COATED. It is approved for ORAL use.
This product is manufactured by SANOFI WINTHROP INDUSTRIE in FRANCE.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.
Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.
Mechanism of Action
Amisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment.
- Bioavailability is 48% following oral administration.
Overdoses of amisulpride have been linked with torsades de pointes.
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide | 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide | Aminosultopride | Amisulprida | Amisulpridum | Amisulpride |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.